<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articles—Germ Cell Tumors
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Dec 19, Darren Feldman, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                                <div class="expert-photo">
                                                    <img class="photo" src="content/img/users/Axel_Grothey_2009_REVISED_tcm8-199717.jpg">
                                                    <!-- <p class="label">Expert</p> -->
                                                </div>
                                                <div class="expert-name">
                                                    <!-- Axel Grothey MD -->
                                                    <a class="fn" href="#">
																										<span class="n">
																											<!-- <span class="honorific-prefix">Dr.</span> -->
																											<span class="given-name">Darren</span>
																											<abbr class="additional-name">R</abbr>
																											<span class="family-name">Feldman</span>
																											<span class="honorific-suffix">MD</span>
																										</span>
																										</a>
                                                    <!--/.fn-->
                                                </div>
                                                <!--/.expert-name-->
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        //NOTE: The content below is the raw html pulled from the original item on OncologySTAT.com
                                        <p>
                                            Based on our expert's review, here are the must-read articles for every
                                            oncologist about patients with germ cell tumors.
                                        </p>
                                        <p>
                                            <strong>
                                                General Review
                                            </strong>
                                        </p>
                                        <p>
                                            1. Journal of Clinical Oncology: Issue on Genitourinary Cancers.
                                            <a href="http://jco.ascopubs.org/content/24/35.toc" target="_blank">J Clin Oncol. 2006;24(35):5479-5621</a>
                                            .
                                        </p>
                                        <p>
                                            2. Bosl GJ, Motzer RJ. Testicular germ-cell cancer.
                                            <a href="http://www.nejm.org/doi/full/10.1056/NEJM199707243370406" target="_blank">N Engl J Med. 1997;337(4):242–253</a>
                                            .
                                        </p>
                                        <p>
                                            3. Kondagunta GV, Motzer RJ. Chemotherapy for advanced germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/24/35/5493.abstract" target="_blank">J Clin Oncol. 2006;24(35):5493-5502</a>
                                            .
                                        </p>
                                        <p>
                                            4. Feldman DR, Bosl GJ, Sheinfeld J, et al. Medical treatment of advanced
                                            testicular cancer.
                                            <a href="http://jama.jamanetwork.com/article.aspx?articleid=181433" target="_blank">JAMA. 2008;299(6):672-684</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            <strong>
                                                Epidemiology/Risk Factors
                                            </strong>
                                        </p>
                                        <p>
                                            5. Lutke-Holzik MF, Rapley EA, Hoekstra HJ, et al. Genetic predisposition
                                            to testicular germ-cell tumours.
                                            <a href="http://www.sciencedirect.com/science/article/pii/S1470204504014937"
                                            target="_blank">Lancet Oncol. 2004;5(6):363-371</a>
                                            .
                                        </p>
                                        <p>
                                            6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.
                                            <a href="http://onlinelibrary.wiley.com/doi/10.3322/caac.20138/full" target="_blank">CA Cancer J Clin. 2012;62(1):10-29</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            7. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship
                                            statistics, 2012.
                                            <a href="http://onlinelibrary.wiley.com/doi/10.3322/caac.21149/full" target="_blank">CA Cancer J Clin. 2012;62(4):220-241</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            8. Daling JR, Doody DR, Sun X, et al. Association of marijuana use and
                                            the incidence of testicular germ cell tumors.
                                            <a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.24159/full" target="_blank">Cancer. 2009;115(6):1215-1223</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            9. Trabert B, Sigurdson AJ, Sweeney AM, et al. Marijuana use and testicular
                                            germ cell tumors.
                                            <a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.25499/full" target="_blank">Cancer. 2011;117(4):848-853</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            <strong>
                                                Underlying Biology
                                            </strong>
                                        </p>
                                        <p>
                                            10. Houldsworth J, Korkola JE, Bosl GJ, et al. Biology and genetics of
                                            adult male germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/24/35/5512.abstract" target="_blank">J Clin Oncol. 2006;24(35):5512-5518</a>
                                            .
                                        </p>
                                        <p>
                                            11. Reuter VE. Origins and molecular biology of testicular germ cell tumors.
                                            <a href="http://www.nature.com/modpathol/journal/v18/n2s/full/3800309a.html"
                                            target="_blank">Mod Pathol. 2005;18(Suppl 2):S51-60</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            <strong>
                                                Staging/Prognosis
                                            </strong>
                                        </p>
                                        <p>
                                            12. Garnick MB. Spurious rise in human chorionic gonadotropin induced
                                            by marihuana in patients with testicular cancer.
                                            <a href="http://www.nejm.org/doi/full/10.1056/NEJM198011133032013" target="_blank">N Engl J Med. 1980;303(20):1177</a>
                                            .
                                        </p>
                                        <p>
                                            13. International Germ Cell Consensus Classification: a prognostic factor-based
                                            staging system for metastatic germ cell cancers. International Germ Cell
                                            Cancer Collaborative Group.
                                            <a href="http://jco.ascopubs.org/content/15/2/594.abstract" target="_blank">J Clin Oncol. 1997;15(2):594-603</a>
                                            .
                                        </p>
                                        <p>
                                            14. Testis. In: Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer
                                            Staging Manual. 7th ed. New York, NY: Springer; 2010:469-478.
                                        </p>
                                        <p>
                                            <strong>
                                                Early-Stage Seminomatous Germ Cell Tumors
                                            </strong>
                                        </p>
                                        <p>
                                            15. Fosså SD, Horwich A, Russell JM, et al. Optimal planning target volume
                                            for stage I testicular seminoma: A Medical Research Council randomized
                                            trial. Medical Research Council Testicular Tumor Working Group.
                                            <a href="http://jco.ascopubs.org/content/17/4/1146.long" target="_blank">J Clin Oncol. 1999;17(4):1146</a>
                                            .
                                        </p>
                                        <p>
                                            16. Jones WG, Fosså SD, Mead GM, et al. Randomized trial of 30 versus
                                            20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report
                                            on Medical Research Council Trial TE18, European Origanisation for the
                                            Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).
                                            <a href="http://jco.ascopubs.org/content/23/6/1200.long" target="_blank">J Clin Oncol. 2005;23(6):1200-1208</a>
                                            .
                                        </p>
                                        <p>
                                            17. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin
                                            versus radiotherapy for stage I seminoma: mature results on relapse and
                                            contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).
                                            <a href="http://jco.ascopubs.org/content/29/8/957.long" target="_blank">J Clin Oncol. 2011;29(8):957-962</a>
                                            .
                                        </p>
                                        <p>
                                            18. Bosl GJ, Patil S. Carboplatin in clinical stage I seminoma: too much
                                            and too little at the same time.
                                            <a href="http://jco.ascopubs.org/content/29/8/949.long" target="_blank">J Clin Oncol. 2011;29(8):949-952</a>
                                            .
                                        </p>
                                        <p>
                                            19. Garcia-del-Muro X, Maroto P, Gumá J, et al. Chemotherapy as an alternative
                                            to radiotherapy in the treatment of stage IIA and IIB testicular seminoma:
                                            a Spanish Germ Cell Cancer Group Study.
                                            <a href="http://jco.ascopubs.org/content/26/33/5416.long" target="_blank">J Clin Oncol. 2008;26(33):5416-5421</a>
                                            .
                                        </p>
                                        <p>
                                            <strong>
                                                Early-Stage Non-Seminomatous Germ Cell Tumors
                                            </strong>
                                        </p>
                                        <p>
                                            20. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin
                                            adjuvant therapy for patients with pathologic stage II germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/13/11/2700.long" target="_blank">J Clin Oncol. 1995;13(11):2700-2704</a>
                                            .
                                        </p>
                                        <p>
                                            21. Kondagunta GV, Motzer RJ. Adjuvant chemotherapy for stage II nonseminomatous
                                            germ-cell tumors.
                                            <a href="http://www.sciencedirect.com/science/article/pii/S0094014307000067"
                                            target="_blank">Urol Clin North Am. 2002;34(2):179-185</a>
                                            .
                                        </p>
                                        <p>
                                            22. Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing
                                            retroperitoneal lymph node dissection with one course of bleomycin and
                                            etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical
                                            stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94
                                            by the German Testicular Cancer Study Group.
                                            <a href="http://jco.ascopubs.org/content/26/18/2966.long" target="_blank">J Clin Oncol. 2008;26(18):2966-2972</a>
                                            .
                                        </p>
                                        <p>
                                            23. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Nonrandomized comparison
                                            of primary chemotherapy and retroperitoneal lymph node dissection for clinical
                                            stage IIA and IIB nonseminomatous germ cell testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/25/35/5597.long" target="_blank">J Clin Oncol. 2007;25(35):5597-5602</a>
                                            .
                                        </p>
                                        <p>
                                            <strong>
                                                Advanced Disease (Nonseminoma and Seminoma)
                                            </strong>
                                        </p>
                                        <p>
                                            <strong>
                                                Good Risk
                                            </strong>
                                        </p>
                                        <p>
                                            24. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide
                                            + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide
                                            + dactinomycin in patients with good-prognosis germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/6/8/1231.abstract" target="_blank">J Clin Oncol. 1988;6(8):1231-1238</a>
                                            .
                                        </p>
                                        <p>
                                            25. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide
                                            and cisplatin versus etoposide and carboplatin in patients with good-risk
                                            germ cell tumors: a multiinstitutional study.
                                            <a href="http://jco.ascopubs.org/content/11/4/598.abstract" target="_blank">J Clin Oncol. 1993;11(4):598-606</a>
                                            .
                                        </p>
                                        <p>
                                            26. Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin
                                            in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative
                                            Oncology Group trial.
                                            <a href="http://jco.ascopubs.org/content/13/2/470.abstract" target="_blank">J Clin Oncol. 1995;13(2):470-476</a>
                                            .
                                        </p>
                                        <p>
                                            27. de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination
                                            chemotherapy for good-prognosis testicular nonseminoma: a randomized study
                                            of the European Organization for Research and Treatment of Cancer Genitourinary
                                            Tract Cancer Cooperative Group.
                                            <a href="http://jco.ascopubs.org/content/15/5/1837.abstract" target="_blank">J Clin Oncol. 1997;15(5):1837-1843</a>
                                            .
                                        </p>
                                        <p>
                                            28. Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin,
                                            etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin
                                            in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional
                                            Medical Research Council/European Organization for Research and Treatment
                                            of Cancer Trial.
                                            <a href="http://jco.ascopubs.org/content/15/5/1844.long" target="_blank">J Clin Oncol. 1997;15(5):1844-1852</a>
                                            .
                                        </p>
                                        <p>
                                            29. Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard
                                            chemotherapy regimens for good-prognosis germ cell tumors: updated analysis
                                            of a randomized trial.
                                            <a href="http://jnci.oxfordjournals.org/content/102/16/1253.long" target="_blank">J Natl Cancer Inst. 2010;102:1253</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            30. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin
                                            chemotherapy for metastatic good-risk germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/23/36/9290.long" target="_blank">J Clin Oncol. 2005;23(36):9290-9294</a>
                                            .
                                        </p>
                                        <p>
                                            31. Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy
                                            regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized
                                            trial of the Genito-Urinary Group of the French Federation of Cancer Centers
                                            (GETUG T93BP).
                                            <a href="http://annonc.oxfordjournals.org/content/18/5/917.long" target="_blank">Ann Oncol. 2007;18(5):917-924</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            <strong>
                                                Intermediate/Poor Risk
                                            </strong>
                                        </p>
                                        <p>
                                            32. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated
                                            germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
                                            <a href="http://www.nejm.org/doi/full/10.1056/NEJM198706043162302" target="_blank">N Engl J Med. 1987;316(23):1435-1440</a>
                                            .
                                        </p>
                                        <p>
                                            33. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin
                                            dose intensity of poor-risk germ cell tumors: a Southeastern Cancer Study
                                            Group and Southwest Oncology Group protocol.
                                            <a href="http://jco.ascopubs.org/content/9/7/1163.abstract" target="_blank">J Clin Oncol. 1991;9(7):1163-1172</a>
                                            .
                                        </p>
                                        <p>
                                            34. De Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus
                                            an alternating regime of PVB and BEP in patients with poor-prognosis metastatic
                                            testicular non-seminoma; a randomized study of the EORTC Genitourinary
                                            Tract Cancer Cooperative Group.
                                            <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033818/" target="_blank">Br J Cancer. 1995;71(6):1311-1314</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            35. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four
                                            cycles of VIP in patients with intermediate-prognosis metastatic testicular
                                            non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer
                                            Cooperative Group. European Organization for Research and Treatment of
                                            Cancer.
                                            <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062963/" target="_blank">Br J Cancer. 1998;78(6):828-832</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            36. Kaye SB, Mead GM, Fosså SD, et al. Intensive induction-sequential
                                            chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis
                                            metastatic nonseminomatous germ cell tumor: a Randomized Medical Research
                                            Council/European Organization for Research and Treatment of Cancer study.
                                            <a href="http://jco.ascopubs.org/content/16/2/692.abstract" target="_blank">J Clin Oncol. 1998;16(2):692-701</a>
                                            .
                                        </p>
                                        <p>
                                            37. Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and
                                            either bleomycin or ifosfamide in the treatment of disseminated germ cell
                                            tumors: final analysis of an intergroup trial.
                                            <a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.11271/abstract;jsessionid=CF71468A738837402A70CF6A86A955E0.d04t02"
                                            target="_blank">Cancer. 2003;97(8):1869-1875</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            38. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial
                                            of conventional-dose chemotherapy with or without high-dose chemotherapy
                                            and autologous hematopoietic stem-cell rescue as first-line treatment for
                                            patients with poor-prognosis metastatic germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/25/3/247.long" target="_blank">J Clin Oncol. 2007;25(3):247-256</a>
                                            .
                                        </p>
                                        <p>
                                            39. Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide
                                            and etoposide combined with double-dose cisplatin and bone marrow support
                                            in patients with high-volume metastatic nonseminomatous germ-cell tumours:
                                            mature results of a randomised trial.
                                            <a href="http://www.sciencedirect.com/science/article/pii/S0302283806013297"
                                            target="_blank">Eur Urol. 2007;51(3):739-746</a>
                                            .
                                        </p>
                                        <p>
                                            40. Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study
                                            comparing standard dose BEP with sequential high-dose cisplatin, etoposide,
                                            and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis
                                            germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal
                                            (EORTC 30974).
                                            <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082158/" target="_blank">Ann Oncol. 2011;22(5):1054-1061</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            41. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating
                                            institution on survival of patients with poor-prognosis metastatic nonseminoma.
                                            European Organization for Research and Treatment of Cancer Genito-Urinary
                                            Tract Cancer Collaborative Group and the Medical Research Council Testicular
                                            Cancer Working Party.
                                            <a href="http://jnci.oxfordjournals.org/content/91/10/839.long" target="_blank">J Natl Cancer Inst. 1999;91(10):839-846</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            42. Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma
                                            with malignant transformation.
                                            <a href="http://jco.ascopubs.org/content/21/23/4285.long" target="_blank">J Clin Oncol. 2003;21(23):4285-4291</a>
                                            .
                                        </p>
                                        <p>
                                            <strong>
                                                Post-Chemotherapy Surgery
                                            </strong>
                                        </p>
                                        <p>
                                            43. Beck SD, Foster RS, Bihrle R, et al. Teratoma in the orchiectomy specimen
                                            and volume of metastasis are predictors of retroperitoneal teratoma in
                                            post-chemotherapy nonseminomatous testis cancer.
                                            <a href="http://www.sciencedirect.com/science/article/pii/S0022534705644588"
                                            target="_blank">J Urol. 2002;168(4 Pt 1):1402-1404</a>
                                            .
                                        </p>
                                        <p>
                                            44. Oldenburg J, Alfsen GC, Lien HH, et al. Postchemotherapy retroperitoneal
                                            surgery remains necessary in patients with nonseminomatous testicular cancer
                                            and minimal residual tumor masses.
                                            <a href="http://jco.ascopubs.org/content/21/17/3310.long" target="_blank">J Clin Oncol. 2003;21(17):3310-3317</a>
                                            .
                                        </p>
                                        <p>
                                            45. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose
                                            positron emission tomography is a reliable predictor for viable tumor in
                                            postchemotherapy seminoma: an update of the prospective multicentric SEMPET
                                            trial.
                                            <a href="http://jco.ascopubs.org/content/22/6/1034.long" target="_blank">J Clin Oncol. 2004;22(6):1034-1039</a>
                                            .
                                        </p>
                                        <p>
                                            46. Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome
                                            after postchemotherapy retroperitoneal lymph node dissection in men with
                                            residual teratoma.
                                            <a href="http://jco.ascopubs.org/content/25/9/1033.long" target="_blank">J Clin Oncol. 2007;25(9):1033-1037</a>
                                            .
                                        </p>
                                        <p>
                                            47. Eggener SE, Carver BS, Loeb S, et al. Pathologic findings and clinical
                                            outcome of patients undergoing retroperitoneal lymph node dissection after
                                            multiple chemotherapy regimens for metastatic testicular germ cell tumors.
                                            <a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.22440/abstract"
                                            target="_blank">Cancer. 2007;109(3):528-535</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            48. Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy
                                            retroperitoneal lymph node dissection: not so easy.
                                            <a href="http://jco.ascopubs.org/content/28/4/519.long" target="_blank">J Clin Oncol. 2010;28(4):519-521</a>
                                            .
                                        </p>
                                        <p>
                                            49. Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of Cisplatin
                                            combination chemotherapy in patients with disseminated nonseminomatous
                                            germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection
                                            needed after complete remission?
                                            <a href="http://jco.ascopubs.org/content/28/4/531.long" target="_blank">J Clin Oncol. 2010;28(4):531-536</a>
                                            .
                                        </p>
                                        <p>
                                            50. Hartmann JT, Candelaria M, Kuczyk MA, et al. Comparison of histological
                                            results from the resection of residual masses at different sites after
                                            chemotherapy for metastatic non-seminomatous germ cell tumours.
                                            <a href="http://www.sciencedirect.com/science/article/pii/S0959804996005175"
                                            target="_blank">Eur J Cancer. 1997;33(6):843-847</a>
                                            .
                                        </p>
                                        <p>
                                            51. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients
                                            with persistent nonteratomatous germ cell tumor in post chemotherapy retroperitoneal
                                            lymph node dissections.
                                            <a href="http://jco.ascopubs.org/content/11/7/1294.long" target="_blank">J Clin Oncol. 2003;11(7):1294-1299</a>
                                            .
                                        </p>
                                        <p>
                                            52. Mosharafa AA, Foster RS, Leibovich BC, et al. Is post-chemotherapy
                                            resection of seminomatous elements associated with higher acute morbidity?
                                            <a href="http://www.sciencedirect.com/science/article/pii/S0022534705635471"
                                            target="_blank">J Urol. 2003;169(6):2126-2128</a>
                                            .
                                        </p>
                                        <p>
                                            <strong>
                                                Relapsed-Disease/Salvage Therapy
                                            </strong>
                                        </p>
                                        <p>
                                            53. Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients
                                            with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience
                                            (1979-1989).
                                            <a href="http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2819910301%2967:5%3C1305::AID-CNCR2820670506%3E3.0.CO;2-J/abstract"
                                            target="_blank">Cancer. 1991;67(5):1305-1310</a>
                                            .
                                        </p>
                                        <p>
                                            54. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide
                                            plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
                                            <a href="http://jco.ascopubs.org/content/16/7/2500.abstract" target="_blank">J Clin Oncol. 1998;16(7):2500-2504</a>
                                            .
                                        </p>
                                        <p>
                                            55. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy
                                            with gemcitabine plus oxaliplatin in patients with intensively pretreated
                                            or refractory germ cell cancer: a study of the German Testicular Cancer
                                            Study Group.
                                            <a href="http://jco.ascopubs.org/content/22/1/108.long" target="_blank">J Clin Oncol. 2004;22(1):108-114</a>
                                            .
                                        </p>
                                        <p>
                                            56. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse
                                            germ cell tumor and outcome to salvage chemotherapy.
                                            <a href="http://jco.ascopubs.org/content/23/28/6999.long" target="_blank">J Clin Oncol. 2005;23(28):6999-7004</a>
                                            .
                                        </p>
                                        <p>
                                            57. Kondagunta GV, Bacik J, Donadio D, et al. Combination of paclitaxel,
                                            ifosfamide, and cisplatin is an effective second-line therapy for patients
                                            with relapsed testicular germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/23/27/6549.long" target="_blank">J Clin Oncol. 2005;23(27):6549-6555</a>
                                            .
                                        </p>
                                        <p>
                                            58. Oldenburg J, Martin JM, Fosså SD. Late relapses of germ cell malignancies:
                                            incidence management, and prognosis.
                                            <a href="http://jco.ascopubs.org/content/24/35/5503.abstract" target="_blank">J Clin Oncol. 2006;24(35):5503-5511</a>
                                            .
                                        </p>
                                        <p>
                                            59. Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel
                                            plus gemcitabine salvage chemotherapy for germ cell tumors after progression
                                            following high-dose chemotherapy with tandem transplant.
                                            <a href="http://jco.ascopubs.org/content/25/5/513.long" target="_blank">J Clin Oncol. 2007;25(5):513-516</a>
                                            .
                                        </p>
                                        <p>
                                            60. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy
                                            and stem-cell rescue for metastatic germ-cell tumors.
                                            <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa067749" target="_blank">N Engl J Med. 2007;357(4):340-348</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            61. Sharp DS, Carver BS, Eggener SE, et al. Clinical outcome and predictors
                                            of survival in late relapse of germ cell tumor.
                                            <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651099/" target="_blank">J Clin Oncol. 2008;26(34):5524-5529</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            62. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high dose chemotherapy
                                            for patients with previously treated germ cell tumors.
                                            <a href="http://jco.ascopubs.org/content/28/10/1706.long" target="_blank">J Clin Oncol. 2010;28(10):1706-1713</a>
                                            .
                                        </p>
                                        <p>
                                            63. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose
                                            chemotherapy in the salvage treatment of patients failing first-line platinum
                                            chemotherapy for advanced germ cell tumours.
                                            <a href="http://annonc.oxfordjournals.org/content/16/7/1152.long" target="_blank">Ann Oncol. 2005;16(7):1152-1159</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            64. International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi
                                            C, et al. Prognostic factors in patients with metastatic germ cell tumors
                                            who experienced treatment failure with cisplatin-based first-line chemotherapy.
                                            <a href="http://jco.ascopubs.org/content/28/33/4906.long" target="_blank">J Clin Oncol. 2010;28(33):4906-4911</a>
                                            .
                                        </p>
                                        <p>
                                            65. Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential
                                            high-dose chemotherapy in patients with relapsed or refractory germ cell
                                            tumors: a prospective randomized multicenter trial of the German Testicular
                                            Cancer Study Group.
                                            <a href="http://jco.ascopubs.org/content/25/19/2778.long" target="_blank">J Clin Oncol. 2007;25(19):2778-2784</a>
                                            .
                                        </p>
                                        <p>
                                            66. Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus
                                            high-dose chemotherapy as first salvage treatment in male patients with
                                            metastatic germ cell tumors: evidence from a large international database.
                                            <a href="http://jco.ascopubs.org/content/29/16/2178.long" target="_blank">J Clin Oncol. 2011;29(16):2178-2184</a>
                                            .
                                        </p>
                                        <p>
                                            67. Kondagunta GV, Sheinfeld J, Motzer RJ. Recommendations of follow-up
                                            after treatment of germ cell tumors.
                                            <a href="http://www.sciencedirect.com/science/article/pii/S0093775403000988"
                                            target="_blank">Semin Oncol. 2003;30(3):382-389</a>
                                            .
                                        </p>
                                        <p>
                                            <strong>
                                                Survivorship
                                            </strong>
                                        </p>
                                        <p>
                                            68. Hartmann JT, Albrecht C, Schmoll HJ, et al. Long-term effects on sexual
                                            function and fertility after treatment of testicular cancer.
                                            <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362282/" target="_blank">Br J Cancer. 1999;80(5-6):801-807</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            69. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced
                                            cardiovascular changes in patients with testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/23/36/9130.long" target="_blank">J Clin Oncol. 2005;23(36):9130-9137</a>
                                            .
                                        </p>
                                        <p>
                                            70. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity
                                            in long-term survivors of metastatic testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/18/8/1725.long" target="_blank">J Clin Oncol. 2000;18(8):1725-1732</a>
                                            .
                                        </p>
                                        <p>
                                            71. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk
                                            of cardiovascular disease in 5-year survivors of testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/24/3/467.full" target="_blank">J Clin Oncol. 2006;24(3):467-475</a>
                                            .
                                        </p>
                                        <p>
                                            72. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome
                                            and disturbances in hormone levels in long-term survivors of disseminated
                                            testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/23/16/3718.long" target="_blank">J Clin Oncol. 2005;23(16):3718-3725</a>
                                            .
                                        </p>
                                        <p>
                                            73. Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576
                                            testicular cancer patients: focus on long-term survivors.
                                            <a href="http://jnci.oxfordjournals.org/content/97/18/1354.long" target="_blank">J Natl Cancer Inst. 2005;97(18):1354-1365</a>
                                            .
                                            <strong>
                                                Free
                                            </strong>
                                        </p>
                                        <p>
                                            74. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific
                                            risks of second malignancies and cardiovascular disease in 5-year survivors
                                            of testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/25/28/4370.full.pdf" target="_blank">J Clin Oncol. 2007;25(28):4370-4378</a>
                                            .
                                        </p>
                                        <p>
                                            75. Dahl AA, Haaland CF, Mykletun A, et al. Study of anxiety disorder
                                            and depression in long-term survivors of testicular cancer.
                                            <a href="http://jco.ascopubs.org/content/23/10/2389.full.pdf" target="_blank">J Clin Oncol. 2005;23(10):2389-2395</a>
                                            .
                                        </p>
                                        <p>
                                        </p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>